[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5483/BMBRep.2017.50.4.165

miR-374 promotes myocardial hypertrophy by negatively regulating vascular endothelial growth factor receptor-1 signaling

Lee, Jong Sub (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))
Song, Dong Woo (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))
Park, Jei Hyoung (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))
Kim, Jin Ock (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))
Cho, Chunghee (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))
Kim, Do Han (School of Life Sciences and Systems Biology Research Center, Gwangju Institute of Science and Technology (GIST))

Publication Information

BMB Reports / v.50, no.4, 2017 , pp. 208-213 More about this Journal

Abstract

Vascular endothelial growth factor (VEGF) is an essential cytokine that has functions in the formation of new blood vessels and regression of cardiac hypertrophy. VEGF/VEGF-receptor-1 (VEGFR1) signaling plays a key role in the regression of cardiac hypertrophy, whereas VEGF/VEGFR2 signaling leads to cardiac hypertrophy. In this study, we identified the prohypertrophic role of miR-374 using neonatal rat ventricular myocytes (NRVMs). Our results showed that overexpression of miR-374 activated G protein-coupled receptor-mediated prohypertrophic pathways by the inhibition of VEGFR1-dependent regression pathways. Luciferase assays revealed that miR-374 could directly target the 3'-untranslated regions of VEGFR1 and cGMP-dependent protein kinase-1. Collectively, these findings demonstrated that miR-374 was a novel pro-hypertrophic microRNA functioning to suppress the VEGFR1-mediated regression pathway.

Keywords

Cardiac hypertrophy; cGMP-dependent protein kinase-1; MicroRNA; Neonatal rat ventricular myocytes; Vascular endothelial growth factor signaling;

Citations & Related Records

Reference

1	Ganesan J, Ramanujam D, Sassi Y et al (2013) MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 127, 2097-2106 DOI
2	Castaldi A, Zaglia T, Di Mauro V et al (2014) MicroRNA-133 modulates the ${\beta}1$ -adrenergic receptor transduction cascade. Circ Res 115, 273-283 DOI
3	Song DW, Ryu JY, Kim JO et al (2014) The miR-19a/b family positively regulates cardiomyocyte hypertrophy by targeting atrogin-1 and MuRF-1. Biochem J 457, 151-162 DOI
4	Carmeliet P and Collen D (2000) Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 902, 249-62
5	Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22 DOI
6	Shiojima I, Sato K, Izumiya Y et al (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115, 2108-2118 DOI
7	Gray DB, Polo-Parada L, Pilar GR et al (1999) A nitric oxide/cyclic GMP-dependent protein kinase pathway alters transmitter release and inhibition by somatostatin at a site downstream of calcium entry. J Neurochem 72, 1981-1990
8	O'Neil RG (2007) VASP: a TRPC4-associated phosphoprotein that mediates PKG-induced inhibition of storeoperated calcium influx. Am J Physiol Renal Physiol 293, F1766-7 DOI
9	Tang KM, Wang GR, Lu P et al (2003) Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 9, 1506-1512 DOI
10	Vandael DH, Mahapatra S, Calorio C, Marcantoni A and Carbone E (2012) Cav1.3 and Cav1.2 channels of adrenal chromaffin cells: emerging views on cAMP/cGMP-mediated phosphorylation and role in pacemaking. Biochim Biophys Acta 1828, 1608-1618
11	Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65, 45-79 DOI
12	Rockman HA, Koch WJ and Lefkowitz RJ (2002) Seventransmembrane-spanning receptors and heart function. Nature 415, 206-212 DOI
13	Jeong MH, Kim SJ, Kang H et al (2015) Cucurbitacin I Attenuates Cardiomyocyte Hypertrophy via Inhibition of Connective Tissue Growth Factor (CCN2) and TGF- ${\beta}$ /Smads Signalings. PLoS One 10, e0136236 DOI
14	Zhou Y, Bourcy K and Kang YJ (2009) Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res 84, 54-63 DOI
15	Heineke J and Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7, 589-600 DOI
16	Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77, 527-543 DOI
17	Zhou Y, Jiang Y and Kang YJ (2008) Copper reverses cardiomyocyte hypertrophy through vascular endothelial growth factor-mediated reduction in the cell size. J Mol Cell Cardiol 45, 106-117 DOI
18	Olsson AK, Dimberg A, Kreuger J and Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7, 359-371 DOI
19	Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 DOI
20	Takahashi T, Ueno H and Shibuya M (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221-2230 DOI
21	Lai EC (2002) Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30, 363-364 DOI
22	Wang J, Liew OW, Richards AM and Chen YT (2016) Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis. Int J Mol Sci 17, 749-769 DOI
23	Kim JO, Song DW, Kwon EJ et al (2015) miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. PLoS One 10, e0122509 DOI
24	Small EM and Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469, 336-342 DOI